Chemomab Therapeutics (CMMB) Interest Expenses (2018 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Interest Expenses came in at $49.9 million in Q4 2025, up 12.75% YoY from $44.2 million in Q4 2024, and up 12.75% on a QoQ basis from $44.2 million in Q4 2024.
Chemomab Therapeutics (CMMB) Interest Expenses (2018 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 8 years of Interest Expenses data on file, last reported at $49.9 million in Q4 2025.
- Quarterly Interest Expenses rose 12.75% year-over-year to $49.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $49.9 million (up 12.75% YoY) and the FY2025 annual result came in at $49.9 million, up 12.75% from the prior year.
- Interest Expenses advanced to $49.9 million in Q4 2025, from $44.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $49.9 million in Q4 2025 to a low of $36.0 million in Q4 2021.
- A 5-year average of $43.0 million and a median of $43.5 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses jumped 14487.04% — and 2024, when it rose 1.72%.
- Tracing CMMB's Interest Expenses over 5 years: stood at $36.0 million in 2021, then climbed by 14.34% to $41.2 million in 2022, then grew by 5.52% to $43.5 million in 2023, then advanced by 1.72% to $44.2 million in 2024, then gained by 12.75% to $49.9 million in 2025.
- The last three Interest Expenses figures came in at $49.9 million (Q4 2025), $44.2 million (Q4 2024), and $43.5 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.86 Mn |
| Dec 31, 2025 | 49.86 Mn |
| Dec 31, 2024 | 44.22 Mn |
| Dec 31, 2024 | 44.22 Mn |
| Dec 31, 2023 | 43.47 Mn |
| Dec 31, 2023 | 43.47 Mn |
| Dec 31, 2022 | 41.20 Mn |
| Dec 31, 2022 | 41.20 Mn |
| Dec 31, 2021 | 36.03 Mn |
| Dec 31, 2021 | 36.03 Mn |
| Dec 31, 2020 | 247,000.00 |
| Dec 31, 2020 | 247,000.00 |
| Dec 31, 2019 | 5,000.00 |
| Dec 31, 2019 | 5,000.00 |
| Sep 30, 2019 | 12.58 Mn |
| Sep 30, 2019 | 12.58 Mn |
| Jun 30, 2019 | 18,000.00 |
| Jun 30, 2019 | 18,000.00 |
| Mar 31, 2019 | 22,000.00 |
| Mar 31, 2019 | 22,000.00 |